MetaVia Inc. (MTVA), a clinical-stage biotechnology company, Tuesday reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 study of DA-1726 for the treatment of obesity.
The Phase 1 study was designed to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects.
In the MAD portion of the study, a clear dose-responsive trend in body weight reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index (BMI) showed a difference between the treatment group and the placebo group, which was even more noticeable, further supporting the dose-dependent effect of the drug on weight-related outcomes. "This new, additional Phase 1 MAD data further highlights DA-1726's potential to be a best-in-class obesity treatment, showing impressive weight loss results, particularly in terms of BMI reduction," said Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.